(Q43239053)

17 November 2017

title

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib (English)

1 reference

17 November 2017

1 reference

9

1 reference

17 November 2017

C Tanaka

1

1 reference

17 November 2017

O Q P Yin

2

1 reference

17 November 2017

V Sethuraman

3

1 reference

17 November 2017

T Smith

4

1 reference

17 November 2017

X Wang

5

1 reference

17 November 2017

K Grouss

6

1 reference

17 November 2017

H Kantarjian

7

1 reference

17 November 2017

F Giles

8

1 reference

17 November 2017

L Galitz

10

1 reference

17 November 2017

H Schran

11

1 reference

17 November 2017

language of work or name

English

0 references

publication date

18 November 2009

1 reference

Clinical Pharmacology & Therapeutics

17 November 2017

published in

1 reference

17 November 2017

volume

87

1 reference

17 November 2017

issue

2

1 reference

17 November 2017

page(s)

197-203

1 reference

Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Thalidomide dose proportionality assessment following single doses to healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Effects of food on the relative bioavailability of lapatinib in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.208

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.208

1 reference

17 November 2017

1 reference